
-
Alnylam Pharmaceuticals NasdaqGS:ALNY Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Location: 675 West Kendall Street, Cambridge, MA, 02142, United States | Website: https://www.alnylam.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
39.8B
Cash
2.632B
Avg Qtr Burn
-11.28M
Short % of Float
2.93%
Insider Ownership
3.83%
Institutional Own.
97.51%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy | Approved Update | |
Leqvio® (inclisiran) Details Transthyretin amyloidosis, Atherosclerotic cardiovascular disease | Approved Quarterly sales | |
Qfitlia™ (fitusiran) Details Hemophilia | Approved Quarterly sales | |
OXLUMO® (lumasiran) Details Primary hyperoxaluria | Approved Quarterly sales | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | Approved Quarterly sales | |
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Cardiomyopathy | Approved Quarterly sales | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | sNDA Resubmission | |
Nucresiran (ALN-TTRsc04) Details Transthyretin amyloidosis | Phase 3 Initiation | |
Mivelsiran (ALN-APP) Details Cerebral Amyloid Angiopathy | Phase 2 Data readout | |
Elebsiran (ALN-HBV02 [VIR-2218] +/- VIR-3434) Details Hepatitis D, Hepatitis B | Phase 2 Data readout | |
Zilebesiran (ALN-AGT) Details Metabolic disorder, Pulmonary arterial hypertension | Phase 2 Data readout | |
Mivelsiran (ALN-APP) Details Alzheimer's disease | Phase 1 Update | |
ALN-HSD Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-PNP Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-KHK Details Type 2 diabetes | Phase 1a Data readout | |
OXLUMO® (lumasiran) Details Kidney disease | Failed Discontinued | |
ALN-XDH Details Arthritis, Chronic refractory gout | Failed Discontinued |